{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:35:09Z","timestamp":1785803709721,"version":"3.56.0"},"reference-count":120,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82305127"],"award-info":[{"award-number":["82305127"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Lung cancer is the most common malignant tumor in the world. Presently, there are still problems, including a high recurrence rate, resistance, and serious toxic side effects, even if conventional treatments like chemotherapy, radiotherapy, and targeted therapy have somewhat improved patient survival. Even though immune checkpoint inhibitors that target programmed cell death-1\/programmed cell death ligand 1 have fundamentally altered the therapeutic paradigm, the core mechanism is strongly linked to tumor immune escape, and some patients continue to have poor response rates or treatment resistance. The mechanisms of immune escape in the immunological microenvironment of lung cancer, involving metabolic reprogramming, overexpression of immune checkpoint molecules, and abnormalities in antigen presentation, are systematically summarized in this review. The article also sums up new therapeutic targets and promising clinical trials. The goal is to provide a solid theoretical foundation for further research into the immune escape mechanism, the creation of new immunotherapeutic targets, and personalized therapeutic strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1597686","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:18:19Z","timestamp":1758773899000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Lung cancer tumor immune microenvironment: analyzing immune escape mechanisms and exploring emerging therapeutic targets"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca-Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/ijms26052049","article-title":"Lung cancer-epidemiology, pathogenesis, treatment and molecular aspect (Review of literature)","volume":"26","author":"Smolarz","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1038\/s41467-023-40745-5","article-title":"Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype","volume":"14","author":"Hiltbrunner","year":"2023","journal-title":"Nat Commun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216726","article-title":"PD-1 regulation in immune homeostasis and immunotherapy","volume":"588","author":"Gao","year":"2024","journal-title":"Cancer Lett"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202306348","article-title":"Brain metastasis from EGFR-mutated non-small cell lung cancer: secretion of IL11 from astrocytes up-regulates PDL1 and promotes immune escape","volume":"11","author":"Tang","year":"2024","journal-title":"Adv Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.09.005","article-title":"Serum taurine affects lung cancer progression by regulating tumor immune escape mediated by the immune microenvironment","volume":"73","author":"Liang","year":"2024","journal-title":"J Adv Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2024.04.006","article-title":"Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities","volume":"45","author":"Konen","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.3390\/ijms25073642","article-title":"Tumor microenvironment: cellular interaction and metabolic adaptations","volume":"25","author":"Benvenuto","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun"},{"key":"B12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40259-024-00657-2","article-title":"Emerging innate immune cells in cancer immunotherapy: promises and challenges","volume":"38","author":"Wu","year":"2024","journal-title":"Biodrugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1038\/s41467-024-48700-8","article-title":"Single-cell and spatial transcriptomics analysis of non-small cell lung cancer","volume":"15","author":"De Zuani","year":"2024","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.10.042","article-title":"Fibroblastic reticular cells generate protective intratumoral T cell environments in lung cancer","volume":"188","author":"Onder","year":"2025","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34921","article-title":"Shaping the immune-suppressive microenvironment on tumor-associated myeloid cells through tumor-derived exosomes","volume":"154","author":"Wang","year":"2024","journal-title":"Int J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1415608","article-title":"Editorial: Analysis of tumor immune microenvironments and molecular mechanism to reveal the dilemma of immunotherapy for advanced non-small cell lung cancer","volume":"15","author":"Roviello","year":"2024","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217272","article-title":"Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma","volume":"604","author":"Huang","year":"2024","journal-title":"Cancer Lett"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41467-025-56546-x","article-title":"Spatially mapping the tumour immune microenvironments of non-small cell lung cancer","volume":"16","author":"Desharnais","year":"2025","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1038\/s41598-025-85532-y","article-title":"Investigating lung cancer microenvironment from cell segmentation of pathological image and its application in prognostic stratification","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep-Uk"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-633","article-title":"Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer","volume":"12","author":"Lim","year":"2023","journal-title":"Transl Lung Cancer R"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-01998-y","article-title":"Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer","volume":"57","author":"Yan","year":"2025","journal-title":"Nat Genet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000389","article-title":"Cancer immunology: immune escape of tumors-expression and regulation of HLA class I molecules and its role in immunotherapies","volume":"30","author":"Wang","year":"2023","journal-title":"Adv Anat Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inibitor response","volume":"11","author":"Montesion","year":"2021","journal-title":"Cancer Discov"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010249","article-title":"Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression","volume":"12","author":"Roerden","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"189126","DOI":"10.1016\/j.bbcan.2024.189126","article-title":"The neoantigens derived from transposable elements - A hidden treasure for cancer immunotherapy","volume":"1879","author":"Hu","year":"2024","journal-title":"Bba-Rev Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"188771","DOI":"10.1016\/j.bbcan.2022.188771","article-title":"CD47: Beyond an immune checkpoint in cancer treatment","volume":"1877","author":"Bian","year":"2022","journal-title":"Bba-Rev Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.019","article-title":"EGFR oncogenic mutations in NSCLC impair macrophage phagocytosis and mediate innate immune evasion through up-regulation of CD47","volume":"19","author":"Hu","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.04.006","article-title":"Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma","volume":"57","author":"De Leo","year":"2024","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-3513","article-title":"H3K18 lactylation potentiates immune escape of non-small cell lung cancer","volume":"84","author":"Zhang","year":"2024","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00636-6","article-title":"Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer","volume":"4","author":"Miller","year":"2023","journal-title":"Nat Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-024-01037-4","article-title":"Acetate reprogrammes tumour metabolism and promotes PD-L1 expression and immune evasion by upregulating c-Myc","volume":"6","author":"Wang","year":"2024","journal-title":"Nat Metab"},{"key":"B35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40364-024-00646-1","article-title":"Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment","volume":"12","author":"Zhang","year":"2024","journal-title":"biomark Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00541-y","article-title":"Metabolic barriers to cancer immunotherapy","volume":"21","author":"DePeaux","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41588-023-01317-x","article-title":"Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers","volume":"55","author":"Yuan","year":"2023","journal-title":"Nat Genet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-021-00378-8","article-title":"Respiratory complex and tissue lineage drive recurrent mutations in tumour mtDNA","volume":"3","author":"Gorelick","year":"2021","journal-title":"Nat Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08439-0","article-title":"Immune evasion through mitochondrial transfer in the tumour microenvironment","volume":"638","author":"Ikeda","year":"2025","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","first-page":"7064","DOI":"10.3390\/ijms24087064","article-title":"R-loops and R-loop-binding proteins in cancer progression and drug resistance","volume":"24","author":"Elsakrmy","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-022-00474-x","article-title":"Sources, resolution and physiological relevance of R-loops and RNA-DNA hybrids","volume":"23","author":"Petermann","year":"2022","journal-title":"Nat Rev Mol Cell Bio"},{"key":"B42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12943-023-01924-6","article-title":"Aberrant R-loop-mediated immune evasion, cellular communication, and metabolic reprogramming affect cancer progression: a single-cell analysis","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-025-01495-0","article-title":"R-loops: a key driver of inflammatory responses in cancer","volume":"57","author":"Lee","year":"2025","journal-title":"Exp Mol Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1644","article-title":"Ribosome heterogeneity and specialization in development","volume":"12","author":"Norris","year":"2021","journal-title":"Wires RNA"},{"key":"B45","doi-asserted-by":"publisher","first-page":"6981","DOI":"10.1016\/j.cell.2024.09.039","article-title":"P-stalk ribosomes act as master regulators of cytokine-mediated processes","volume":"187","author":"Dopler","year":"2024","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009934","article-title":"Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy","volume":"12","author":"Li","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1655","article-title":"PI3K\/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6(high) uterine leiomyosarcoma to PD-1 blockade","volume":"14","author":"De Wispelaere","year":"2024","journal-title":"Clin Transl Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"111561","DOI":"10.1016\/j.celrep.2022.111561","article-title":"OTUB2 exerts tumor-suppressive roles via STAT1-mediated CALML3 activation and increased phosphatidylserine synthesis","volume":"41","author":"Chang","year":"2022","journal-title":"Cell Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41467-023-44466-7","article-title":"Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1","volume":"15","author":"Ren","year":"2024","journal-title":"Nat Commun"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8359860","article-title":"PRDX2 promotes the proliferation and metastasis of non-small cell lung cancer in vitro and in vivo","volume":"2020","author":"Chen","year":"2020","journal-title":"BioMed Res Int"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.79852","article-title":"Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity","volume":"19","author":"Zheng","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12967-024-05888-z","article-title":"PRDX2 induces tumor immune evasion by modulating the HDAC3-Galectin-9 axis in lung adenocarcinoma cells","volume":"23","author":"Dong","year":"2025","journal-title":"J Transl Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s12967-024-05242-3","article-title":"Choline metabolism reprogramming mediates an immunosuppressive microenvironment in non-small cell lung cancer (NSCLC) by promoting tumor-associated macrophage functional polarization and endothelial cell proliferation","volume":"22","author":"Xiao","year":"2024","journal-title":"J Transl Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13046-024-02968-2","article-title":"Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape","volume":"43","author":"Scafetta","year":"2024","journal-title":"J Exp Clin Canc Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"8895","DOI":"10.1038\/s41467-024-53039-1","article-title":"Targeting IRE1alpha reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer","volume":"15","author":"Unal","year":"2024","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41467-022-35584-9","article-title":"Tumor-intrinsic IRE1alpha signaling controls protective immunity in lung cancer","volume":"14","author":"Crowley","year":"2023","journal-title":"Nat Commun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.08.015","article-title":"Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation","volume":"57","author":"Nian","year":"2024","journal-title":"Immunity"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp0719","article-title":"ACSL6-activated IL-18R1-NF-kappaB promotes IL-18-mediated tumor immune evasion and tumor progression","volume":"10","author":"Di","year":"2024","journal-title":"Sci Adv"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859738","article-title":"IL-9 producing tumor-infiltrating lymphocytes and treg subsets drive immune escape of tumor cells in non-small cell lung cancer","volume":"13","author":"Heim","year":"2022","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2024.106.23","article-title":"Research progresses on the effects of CCL4 on immune escape in the tumor microenvironment","volume":"27","author":"Chen","year":"2024","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B61","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-030-36667-4_3","article-title":"CCL4 signaling in the tumor microenvironment","volume":"1231","author":"Mukaida","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-02913-9","article-title":"Expression and potential role of CCL4 in CD8+T cells in NSCLC","volume":"24","author":"Chen","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12943-024-02201-w","article-title":"The miR-23a\/27a\/24\u20132 cluster drives immune evasion and resistance to PD-1\/PD-L1 blockade in non-small cell lung cancer","volume":"23","author":"Luo","year":"2024","journal-title":"Mol Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-013-1584-3","article-title":"The function of EMSY in cancer development","volume":"35","author":"Hou","year":"2014","journal-title":"Tumour Biol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.005","article-title":"EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion","volume":"185","author":"Marzio","year":"2022","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177421","article-title":"Overexpression or knockdown of the P2X7 receptor regulates the progression of non-small cell lung cancer, involving GSK-3beta and JNK signaling pathways","volume":"995","author":"Yu","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.149513","article-title":"The impact of the P2X7 receptor on the tumor immune microenvironment and its effects on tumor progression","volume":"707","author":"Zou","year":"2024","journal-title":"Biochem Bioph Res Co"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1287310","article-title":"Tumour immune escape via P2X7 receptor signalling","volume":"14","author":"Sainz","year":"2023","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"13906","DOI":"10.3390\/ijms241813906","article-title":"The P2X7 receptor in oncogenesis and metastatic dissemination: new insights on vesicular release and adenosinergic crosstalk","volume":"24","author":"Adinolfi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/s41419-020-03200-7","article-title":"SKIL facilitates tumorigenesis and immune escape of NSCLC via upregulating the TAZ\/autophagy axis","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death Dis"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/s41423-020-00570-y","article-title":"CD147 regulates antitumor CD8(+) T-cell responses to facilitate tumor-immune escape","volume":"18","author":"Chen","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc3911","article-title":"Down-regulation of A20 promotes immune escape of lung adenocarcinomas","volume":"13","author":"Breitenecker","year":"2021","journal-title":"Sci Transl Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0442","article-title":"Morphine-3-glucuronide upregulates PD-L1 expression via TLR4 and promotes the immune escape of non-small cell lung cancer","volume":"18","author":"Wang","year":"2021","journal-title":"Cancer Biol Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41419-021-04124-6","article-title":"Notch1\/TAZ axis promotes aerobic glycolysis and immune escape in lung cancer","volume":"12","author":"Xie","year":"2021","journal-title":"Cell Death Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12943-021-01411-w","article-title":"Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms","volume":"20","author":"Jiang","year":"2021","journal-title":"Mol Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002746","article-title":"LINC01140 promotes the progression and tumor immune escape in lung cancer by sponging multiple microRNAs","volume":"9","author":"Xia","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215867","article-title":"FGFR1\/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression","volume":"547","author":"Hu","year":"2022","journal-title":"Cancer Lett"},{"key":"B78","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12964-022-00934-z","article-title":"Alpha5 nicotinic acetylcholine receptor-mediated immune escape of lung adenocarcinoma via STAT3\/Jab1-PD-L1 signalling","volume":"20","author":"Zhu","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B79","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s11658-022-00343-7","article-title":"Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR\/PD-L1\/USP8 axis","volume":"27","author":"Huang","year":"2022","journal-title":"Cell Mol Biol Lett"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108629","article-title":"Estradiol initiates the immune escape of non-small cell lung cancer cells via ERbeta\/SIRT1\/FOXO3a\/PD-L1 axis","volume":"107","author":"Song","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141797","article-title":"SIRPgamma-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling","volume":"132","author":"Xu","year":"2022","journal-title":"J Clin Invest"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104495","article-title":"TIGIT: Will it be the next star therapeutic target like PD-1 in hematological Malignancies","volume":"204","author":"Liu","year":"2024","journal-title":"Crit Rev Oncol Hemat"},{"key":"B83","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1158\/2159-8290.CD-RW2021-170","article-title":"An anti-TIGIT antibody with a PD-1 inhibitor shows promise in solid tumors","volume":"12","year":"2022","journal-title":"Cancer Discov"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer","volume":"33","author":"Niu","year":"2022","journal-title":"Ann Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2397","article-title":"Pharmacokinetics (PK) of tiragolumab in first-in-human study in patients with mixed solid tumors (GO30103)","volume":"64","author":"Garralda","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.annonc.2022.06.013","article-title":"Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches","volume":"33","author":"Cortiula","year":"2022","journal-title":"Ann Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01363","article-title":"SKYSCRAPER-02: tiragolumab in combination with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer","volume":"42","author":"Rudin","year":"2024","journal-title":"J Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.956090","article-title":"The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application","volume":"13","author":"Huo","year":"2022","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.785091","article-title":"Immune checkpoint LAG3 and its ligand FGL1 in cancer","volume":"12","author":"Shi","year":"2021","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1349081","article-title":"Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy","volume":"14","author":"Su","year":"2023","journal-title":"Front Pharmacol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02965-0","article-title":"Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial","volume":"30","author":"Schuler","year":"2024","journal-title":"Nat Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01539-5","article-title":"Dostarlimab: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"DRUGS"},{"key":"B94","doi-asserted-by":"publisher","first-page":"7301","DOI":"10.1038\/s41467-023-42900-4","article-title":"Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial","volume":"14","author":"Lim","year":"2023","journal-title":"Nat Commun"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1158\/0008-5472.CAN-23-3553","article-title":"Oncogenic calreticulin induces immune escape by stimulating TGFbeta expression and regulatory T-cell expansion in the bone marrow microenvironment","volume":"84","author":"Schmidt","year":"2024","journal-title":"Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00521-1","article-title":"Tumor in the crossfire: inhibiting TGF-beta to enhance cancer immunotherapy","volume":"36","author":"Tschernia","year":"2022","journal-title":"Biodrugs"},{"key":"B97","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1186\/s12885-023-11153-1","article-title":"A phase Ib\/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer","volume":"23","author":"Nadal","year":"2023","journal-title":"BMC Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1130358","article-title":"Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer","volume":"14","author":"Kowash","year":"2023","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03430-6","article-title":"First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors","volume":"72","author":"Bendell","year":"2023","journal-title":"Cancer Immunol Immun"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007340","article-title":"Phase 1\/2 study of monalizumab plus durvalumab in patients with advanced solid tumors","volume":"12","author":"Patel","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"J Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2354160","article-title":"PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer","volume":"20","author":"Barlesi","year":"2024","journal-title":"Future Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1079","article-title":"A B7-H4-targeting antibody-drug conjugate shows antitumor activity in PARPi and platinum-resistant cancers with B7-H4 expression","volume":"30","author":"Gitto","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007572","article-title":"SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models","volume":"11","author":"Gray","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adf2223","article-title":"Beyond T cell exhaustion: TIM-3 regulation of myeloid cells","volume":"9","author":"Dixon","year":"2024","journal-title":"Sci Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01218-y","article-title":"New checkpoint inhibitors on the road: targeting TIM-3 in solid tumors","volume":"24","author":"Gomes De Morais","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0884","article-title":"Combined targeting of PD-1 and TIM-3 in patients with locally advanced or metastatic melanoma: AMBER cohorts 1c, 1e, and 2A","volume":"31","author":"Davar","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1504139","article-title":"Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions","volume":"14","author":"Ding","year":"2024","journal-title":"Front Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13046-024-03124-6","article-title":"Galectin-3 induces pathogenic immunosuppressive macrophages through interaction with TREM2 in lung cancer","volume":"43","author":"Wang","year":"2024","journal-title":"J Exp Clin Canc Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3390\/cancers17050906","article-title":"Targeting immune checkpoint inhibitors for non-small-cell lung cancer: beyond PD-1\/PD-L1 monoclonal antibodies","volume":"17","author":"Roussot","year":"2025","journal-title":"CancerS"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"New Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"New Engl J Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"Jama-J Am Med Assoc"},{"key":"B114","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1056\/NEJMc2313778","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"390","author":"Horita","year":"2024","journal-title":"New Engl J Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01891","article-title":"Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02747","article-title":"Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor\u2013Resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer","volume":"42","author":"Yang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00264-9","article-title":"Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged >\/=70 years or with an ECOG performance status of 2 (GFPC 08\u20132015 ENERGY): a randomised, open-label, phase 3 study","volume":"13","author":"Lena","year":"2025","journal-title":"Lancet Resp Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07121-9","article-title":"Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells","volume":"627","author":"Guan","year":"2024","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1597686\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:18:22Z","timestamp":1758773902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1597686\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":120,"alternative-id":["10.3389\/fimmu.2025.1597686"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1597686","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1597686"}}